The second edition of the World Health Organization (WHO) consolidated guidelines on the use of antiretrovirals (ARVs) updates the 2013 edition following an extensive review of evidence undertaken in 2015. Experience from country programmes, consultations with communities and modelling of potential impact have informed the ...

The Prequalification of Medicines Programme (PQP) • A United Nations Programme managed by WHO • Started in March 2001 as a Pilot Project: Focus on HIV/AIDS • Partners included WHO, UNICEF, UNFPA, UNAIDS and supported by World Bank • Quickly expanded to include Tuberculosis, Malaria, Reproductive Health, Influenza and ...

PEPFAR’s Evolution. From Emergency Response to Sustainable Impact for an AIDS-free Generation. 2003-2007: PEPFAR 1 Emergency Response Delivering prevention, care and treatment services Building and strengthening health systems to deliver HIV services 2008-2012: PEPFAR 2 Shift to sustainable response Shared responsibility and country driven programs Scaling up core interventions (ART, PMTCT, and VMMC) ...

Purpose of the new PQ financing strategy: • Maintain the overall objective of PQ to provide assured safe, efficacious and quality drugs, vaccines, diagnostics and devices while increasing supply and access; • Need for an innovative, practical and sustainable funding approach for the WHO PQ programme; • Reduce ...

Currently does not include estimates of number of people who may need PrEP (e.g. number of IDUs at high risk of HIV acquisition) or TasP • Borrows average usage forecast from currently available forecasts till 2018 • Borrows epidemiological estimates from available estimates till 2018 • Assumptions: – Linear ...

Background: Extent and timing of public health usage of ARVs, especially new drugs, was a key area for the MPP to understand when we commenced our licensing work with originator and generic companies • MPP started its forecasting exercise in 2011, including all ARVs but focusing on ...

WHO/UNAIDS Consultation with manufacturers. March 2015, Geneva, Switzerland Key Points • The IATT Optimal Formulary is designed to guide selection and procurement of paediatric ARV’s around a subset of optimal products • Consolidation of demand stabilizes supplies of paediatric ARVs • Success requires global consensus, cooperation with the manufacturers, ...

Forecasting demand for ARV's trends of pediatric formularions uptake from the GPRM Database

Update on the Global Fund’s Procurement Strategy. WHO UNAIDS Annual Meeting with Pharmaceutical Stakeholders Key outcomes The long term collaborative agreements will support continuous supply through improved lead times and better delivery performance Supply risks mitigated with multiple awardees per product and diversification of API sources ...

Objectives: Promote access to life saving medicines and informed the WHO guideline Process; Work with all concerned parties to remove or minimize obstacles for medicines entering the market and facilitate their uptake; Provide partners and players in the field of SCM with reliable data to ...

Presented at WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders in March 19-20, 2015

Forecasting demand for ARV's is the current API production capacity sufficient to meet the growing ARV demand for a smooth procurement?

The global effort to scale-up HIV treatment in low- and middle-income countries continues to move closer towards achieving the goal of 15 million people receiving treatment by 2015. By the end of 2012, 9.7 million people in low- and middle-income countries were receiving antiretroviral therapy ...